Side-by-side · Research reference

LiraglutidevsMelanotan-II

Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.

AFDA-ApprovedVerified14/45 cited

BPhase 1Reviewed9/43 cited

Liraglutide

Daily GLP-1 RA · FDA-Approved

0.6–3.0 mgDaily doseSAXENDA (liraglutide) injectio 2014

5–10%Body-weight ↓SAXENDA (liraglutide) injectio 2014

~13 hrHalf-lifeSAXENDA (liraglutide) injectio 2014

SQ · Abdomen / thigh / arm · Once daily

Melanotan-II

MC1R + MC4R agonist · Tanning + sexual response

0.25–1.0 mgPer doseDorr 1996

Phase 1Evidence levelDorr 1996

~1 hrHalf-life

SQ · Abdomen · Loading 5–7 days, then maintenance

01Mechanism of Action

Parameter

Liraglutide

Melanotan-II

Primary target

GLP-1 receptor (GLP-1R)SAXENDA (liraglutide) injectio 2014

MC1R (skin) + MC3R + MC4R (CNS sexual / appetite)Dorr 1996

Pathway

GLP-1R agonism → ↑glucose-dependent insulin, ↓glucagon, ↓gastric emptying, ↓appetiteSAXENDA (liraglutide) injectio 2014 Marso 2016

MC1R agonism → melanocyte tyrosinase → eumelanin synthesis. MC4R → autonomic sexual arousal centresDorr 1996 Simerly 2023

Downstream effect

Glycemic improvement, modest body-weight reduction, cardiovascular event reduction in high-risk T2DMarso 2016

Skin darkening, photo-protection, increased sexual desire / spontaneous erectionDorr 1996

Feedback intact?

Glucose-dependent insulin release preserves physiological feedback

—

Origin

Modified GLP-1(7-37) with Lys26 substitution (Arg34) and C-16 palmitoyl-glutamate acylation for albumin bindingSAXENDA (liraglutide) injectio 2014

Cyclic 7-AA modified α-MSH analog; designed at University of ArizonaDorr 1996

Antibody development

—

02Dosage Protocols

Parameter

Liraglutide

Melanotan-II

Standard dose (T2D, Victoza)

1.2–1.8 mg / daySAXENDA (liraglutide) injectio 2014

—

Standard dose (weight, Saxenda)

3.0 mg / day (after 5-week titration)SAXENDA (liraglutide) injectio 2014

—

Frequency

Once daily, same time each day

Daily during loading; 1–2× per week maintenance

Titration schedule

0.6 → 1.2 → 1.8 → 2.4 → 3.0 mg over 5 weeks

Mitigates GI side effects.

—

Evidence basis

FDA-approved · Phase 3 RCTs (LEADER, SCALE)Marso 2016 SAXENDA (liraglutide) injectio 2014

Phase 1 + anecdotalDorr 1996

Duration

Indefinite for chronic indication

8–12 weeks per cycle

Reconstitution

Pre-filled commercial pen (no reconstitution)

Bacteriostatic water; protect from light

Timing

Any time of day; consistent

Evening preferred (24h tan-development cycle)

Half-life

~13 hrSAXENDA (liraglutide) injectio 2014

~1 hour plasma; effects on melanocytes persist days

Loading phase

—

0.25–0.5 mg/day SQ × 5–7 daysDorr 1996

Builds up to visible tan.

Maintenance

—

0.5–1.0 mg 1–2×/week

After visible tan develops; supports with UV exposure.

Lower / starter dose

—

0.1 mg / day

Conservative starter — assess tolerability for nausea.

04Side Effects & Safety

Parameter

Liraglutide

Melanotan-II

GI symptoms

Nausea, vomiting, diarrhea (very common during titration)SAXENDA (liraglutide) injectio 2014

—

Pancreatitis risk

Rare; discontinue if suspected

—

Thyroid C-cell tumours

Boxed warning — contraindicated in MEN2 / MTC historySAXENDA (liraglutide) injectio 2014

—

Hypoglycemia

Low risk as monotherapy; elevated with sulfonylureas / insulin

—

Heart rate

Modest ↑ resting HR (~2-3 bpm)

—

Cardiovascular benefit

↓ MACE in high-risk T2D (LEADER trial)Marso 2016

—

Pregnancy / OB

Contraindicated

Nausea

—

Common, especially loading phase

Flushing

—

Common transient

Spontaneous erection

—

Common in men — MC4R cross-effectDorr 1996

Increased mole / freckle pigmentation

—

Existing moles darken; new lesions possible

Melanoma risk

—

Theoretical concern — increased melanocyte activity; CAUTION in melanoma history

Appetite suppression

—

MC4R-mediated; mild

Absolute Contraindications

Liraglutide

·MTC personal or family history; MEN2
·Pregnancy / breastfeeding
·Hypersensitivity to liraglutide

Melanotan-II

·History of melanoma or atypical mole syndrome
·Pregnancy / breastfeeding
·Active uncontrolled hypertension

Relative Contraindications

Liraglutide

·Severe gastroparesis
·History of pancreatitis
·Severe gastrointestinal disease

Melanotan-II

·Significant freckling / dysplastic nevus
·Personal or family melanoma history

05Administration Protocol

Parameter

Liraglutide

Melanotan-II

1. Reconstitution / device

Commercial pre-filled pen, no reconstitution required.

Add 2 mL bacteriostatic water to 10 mg vial → 5 mg/mL = 500 mcg per 0.1 mL. Light-protected.

2. Injection site

SQ — abdomen, thigh, or upper arm. Rotate sites.

SQ — abdomen. Rotate sites.

3. Timing

Once daily, same time each day. Take with or without food.

Evening preferred. UV exposure (sunlight or tanning bed) helps develop tan.

4. Storage

Refrigerate 2–8 °C unopened; room temp ≤30 °C up to 30 days after first use.

Lyophilised: refrigerate, light-protected. Reconstituted: refrigerate ≤30 days.

5. Needle

Pen-supplied 32G needle.

29–31G insulin syringe.